Welcome to our dedicated page for Icu Medical SEC filings (Ticker: ICUI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ICU Medical, Inc. (Nasdaq: ICUI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, together with AI-powered tools to help interpret them. ICU Medical is a medical technology company headquartered in San Clemente, California, and describes itself as a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings.
ICU Medical files periodic and current reports with the U.S. Securities and Exchange Commission, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. For example, the company has filed Form 8-K reports to furnish press releases announcing its quarterly financial results. These filings provide detail on total revenues, cost of goods sold, gross profit, operating expenses, product line revenues for Consumables, Infusion Systems and Vital Care, net income or loss, cash flows and non-GAAP measures such as adjusted EBITDA and adjusted diluted earnings per share.
On Stock Titan, AI-generated summaries can highlight key elements of ICU Medical’s filings, helping users quickly understand disclosures related to product line performance, restructuring and integration expenses, contract manufacturing, joint ventures such as Otsuka ICU Medical LLC, and the risk factors the company describes in its Form 10-K and subsequent filings. Real-time updates from EDGAR ensure that new ICUI filings, including Forms 10-K, 10-Q, 8-K and other relevant documents, are added as they become available.
The filings page can also be used to review information that underlies the company’s press releases, such as the 8-K items that reference earnings announcements. By combining official SEC documents with AI explanations, this resource helps investors and analysts navigate ICU Medical’s financial reporting, segment disclosures and regulatory communications without having to manually parse every line of each filing.
ICU Medical Chairman and CEO Vivek Jain reported multiple equity award transactions. On March 8, 2026, he exercised 107,635 performance shares at $0.00 per share, acquiring the same number of common shares, which were earned at 250% of target PRSU performance after Compensation Committee certification.
That same day, 59,500 common shares were disposed of at $132.00 per share to satisfy tax obligations through share withholding, not an open-market sale. On March 7, 2026, he exercised awards covering 5,282 shares twice (derivative and non-derivative reporting), and 2,919 shares were withheld for taxes. Following these events, he also reported 152,339 common shares held indirectly through a trust.
ICU Medical Chief Information Officer Ben Sousa reported multiple equity award transactions. On 3/7/26 and 3/8/26, he acquired common stock through the exercise or settlement of Restricted Stock Units and performance-based Restricted Stock Units, including 7,177 performance shares earned at 250% of target following Compensation Committee certification.
On both dates, some common shares were disposed of in transactions coded “F” at a price of $132 per share, representing shares withheld to satisfy tax obligations rather than open-market sales. After these transactions, Sousa directly owned 4,744 shares of ICU Medical common stock.
ICU Medical (ICUI) VP and General Counsel Virginia Ruth Sanzone reported equity award activity involving restricted and performance-based stock units. On March 7 and 8, 2026, she acquired multiple blocks of Common Stock through exercises or conversions of derivative awards, including 23,917 Performance Shares and several smaller tranches.
The filing also shows dispositions of Common Stock coded as tax-withholding events, with 13,221 shares and 1,762 shares delivered at a price of $132.00 per share to satisfy exercise price or tax liabilities. A performance stock unit grant dated March 8, 2024 was certified at 250% of target on February 11, 2026, resulting in the shares acquired. Footnotes explain that these awards are restricted stock units and performance-based restricted stock units with no purchase or exercise price and time-based vesting over three years.
ICU Medical (ICUI) executive Daniel Woolson reported multiple equity award settlements and related tax-withholding transactions. On March 7–8, 2026, he acquired ICU Medical common stock through the exercise or conversion of performance-based and other restricted stock units at an exercise price of $0.00 per share.
The filing shows Performance-based Restricted Stock Units (PRSUs) granted on March 8, 2024 were earned at 250% of target after the Compensation Committee certified performance results on February 11, 2026, resulting in common shares being issued. Code F entries reflect tax-withholding dispositions of common shares at $132.00 per share, leaving Woolson with directly owned common stock as reported after each transaction.
ICU Medical Chief Operating Officer Christian B. Voigtlander reported equity award activity involving performance-based and time-based stock units. On 3/8/2026, he exercised 71,757 performance shares at $0 per share, converting them into 71,757 shares of common stock, and his direct common stock holdings increased to 79,421 shares.
As part of this activity, 39,667 shares of common stock were disposed of at $132 per share to satisfy tax withholding obligations, leaving 39,754 shares directly owned afterward. On 3/7/2026, he also exercised 3,522 performance-based restricted stock units for 3,522 common shares, with 1,946 shares withheld at $132 per share for taxes. Footnotes explain that these awards are restricted and performance-based units with no purchase or exercise price, and recent performance certification caused the PRSUs granted on 3/8/2024 to be earned at 250% of target.
ICU Medical, Inc. reported that its Board’s Compensation Committee approved an amendment to the company’s Executive Severance Plan. The amendment, effective as of December 31, 2025, extends the plan’s expiration date by three years, from December 31, 2025 to December 31, 2028.
The Executive Severance Plan governs severance benefits for certain senior executives, so extending its term maintains the existing framework for executive departure protections. The full text of the Third Amendment to the Executive Severance Plan is provided as an exhibit and is incorporated by reference.
ICU Medical describes its 2025 business, strategy and risks as a global provider of infusion therapy, vascular access and vital care products. The company now operates through Consumables, Infusion Systems and Vital Care, selling to hospitals, distributors and alternate‑site providers in more than 100 countries.
ICU highlights the 2022 acquisition of Smiths Medical and the 2019 Pursuit Vascular deal, as well as a 2025 transaction forming a joint venture with Otsuka, under which it sold 60% of its IV Solutions business while retaining 40% and commercial responsibilities. Management emphasizes ongoing R&D investment, strong regulatory oversight in the U.S. and EU, and risks from inflation, foreign exchange, trade policy, FDA compliance, cybersecurity, supplier concentration and high leverage from the Smiths Medical acquisition.
ICU Medical reported fourth quarter 2025 revenue of $540.7 million, down from $629.8 million a year earlier, mainly reflecting the prior divestiture of its IV Solutions business within the Vital Care line. Despite lower revenue, GAAP gross margin improved to 38% from 36%.
The company posted a GAAP net loss of $15.7 million, or $(0.64) per diluted share, narrowing from a $23.8 million loss in 2024. On a non-GAAP basis, adjusted EBITDA was $98.2 million and adjusted diluted EPS was $1.91, both below the prior year.
For full-year 2025, ICU Medical generated $2.23 billion in revenue and modest GAAP net income of $0.7 million, supported by a gain on a business sale and strong operating cash flow of $179.8 million. The company reduced long-term debt and ended the year with $308.0 million in cash.
Looking to fiscal 2026, management guides GAAP net income between $26 million and $44 million and GAAP EPS between $1.03 and $1.74. ICU Medical expects adjusted EBITDA of $400–$430 million and adjusted EPS of $7.75–$8.45, assuming continued non-GAAP adjustments for items like stock compensation, amortization, restructuring, and quality-related remediation.
ICU Medical, Inc. (ICUI) insider transaction: company officer Daniel Woolson, listed as VP, GM-Infusion Capital, reported selling 2,897 shares of ICUI common stock in an open market transaction on 11/25/2025, at a price of $152.3522 per share. After this sale, he beneficially owns 11,297 shares of ICU Medical common stock.
ICU Medical (ICUI) Form 4: Director Elisha W. Finney exercised 1,285 non-qualified stock options at $103.76 and, on the same day (11/11/2025), sold 1,285 shares at $140.42. Following these transactions, she directly owns 3,995 shares.
The option carried a $103.76 exercise price, became exercisable on 06/15/2016, and expires on 01/08/2026; derivative securities beneficially owned after the transactions were 0.